MartinEduardoGutierrezMD

Director Drug Discovery/Phase I Research Chief of Thoracic Oncology Member of GI Division

Overview of Dr. Gutierrez

As co-chief, Thoracic Oncology, and director of the Phase 1 Program, I specialize in bringing Phase 1 clinical trials to cancer patients treated at John Theurer Cancer Center. The approximately 40 Phase 1 trials currently in place are focused on immunotherapy, targeted therapies, and cell technologies such as CAR-T therapy, which engineers T-cells to target cancer.

Office
92 2nd Street
Hackensack, NJ 07601
Book by Phone+1(551) 209-3960
Is this information wrong?

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1997 - 2000
Boston University Medical CenterResidency, Internal Medicine, 1993 - 1996
Pontifical Xavierian UniversityClass of 1991

Certifications & Licensure

NJ State Medical License 2011 - 2025
NY State Medical License 2021 - 2024
FL State Medical License 2000 - 2014
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

Study of Neoadjuvant CT With Selective Radiotherapy in Patients With Intermediate-Risk Cancer Rectum Start of enrollment: 2009 Mar 01
Completed
Phase 2
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies Start of enrollment: 2014 Feb 01
Completed
Phase 1
A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer Start of enrollment: 2018 Mar 07
Recruiting
Phase 2
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer Start of enrollment: 2012 Nov 23
Completed
Phase 2
Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients Start of enrollment: 2013 Apr 01
Completed
Phase 1
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma Start of enrollment: 2013 Mar 01
Completed
Phase 1
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Start of enrollment: 2013 Aug 01
Completed
Phase 2
Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers Start of enrollment: 2013 Apr 01
Terminated
Phase 1, Phase 2
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors Start of enrollment: 2013 Nov 01
Completed
Phase 1
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
No longer available
Testing Spectrosense EVA System for Detection of Pancreatic Cancer by Analyzing Volatile Organic Compounds (VOCs) in Exhaled Air Start of enrollment: 2013 Oct 01
Unknown status
Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors Start of enrollment: 2014 Feb 01
Completed
Phase 1
Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment Start of enrollment: 2014 Apr 01
Completed
Phase 1
LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel Start of enrollment: 2014 Jul 01
Withdrawn
Phase 1
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors Start of enrollment: 2017 Feb 23
Terminated
Phase 1
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors Start of enrollment: 2018 Oct 01
Completed
Phase 1, Phase 2
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies Start of enrollment: 2019 May 17
Recruiting
Phase 1
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas Start of enrollment: 2019 Sep 18
Recruiting
Phase 1, Phase 2
A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations Start of enrollment: 2022 Apr 18
Active, not recruiting
Phase 1
Roles: Contact
A Study of SGN-EGFRd2 in Advanced Solid Tumors Start of enrollment: 2023 Nov 14
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors.
Maxime Chénard-Poirier, Aaron R Hansen, Martin E Gutierrez, Drew Rasco, Yan Xing, Lin-Chi Chen, Heng Zhou, Andrea L Webber, Tomoko Freshwater, Manish R Sharma> ;Investigational New Drugs. 2024 Mar 14
1 citations
Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma.
Andrew Ip, Alessandra Petrillo, Alexandra Della Pia, Geeny G Lee, Sarvarinder Gill, Tony Varughese, Joshua Zenreich, Martin Gutierrez, Jiayu Zhang, Jaeil Ahn, Vishnu B...> ;Leukemia & Lymphoma. 2023 Dec 1
12 citations
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
Shubham Pant, Martin Schuler, Gopa Iyer, Olaf Witt, Toshihiko Doi, Shukui Qin, Josep Tabernero, David A Reardon, Christophe Massard, Anna Minchom, Iwona Lugowska, Omar...> ;The Lancet. Oncology. 2023 Aug 1
2 citations
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results.
Martin Gutierrez, Wei-Sen Lam, Matthew D Hellmann, Matthew A Gubens, Charu Aggarwal, Daniel Shao Weng Tan, Enriqueta Felip, Joanne W Y Chiu, Jong-Seok Lee, James Chih-...> ;Nature Medicine. 2023 Jul 1
3 citations
Combining cell-free RNA with cell-free DNA in liquid biopsy for hematologic and solid tumors.
Maher Albitar, Hong Zhang, Ahmad Charifa, Andrew Ip, Wanlong Ma, James McCloskey, Michele Donato, David Siegel, Stanley Waintraub, Martin Gutierrez, Andrew Pecora, And...> ;Heliyon. 2023 May 1
8 citations
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis.
H Borghaei, T-E Ciuleanu, J-S Lee, A Pluzanski, R Bernabe Caro, M Gutierrez, Y Ohe, M Nishio, J Goldman, N Ready, D R Spigel, S S Ramalingam, L G Paz-Ares, J F Gainor,...> ;Annals of Oncology. 2023 Feb 1
7 citations
Differential Diagnosis of Hematologic and Solid Tumors Using Targeted Transcriptome and Artificial Intelligence.
Hong Zhang, Muhammad A Qureshi, Mohsin Wahid, Ahmad Charifa, Aamir Ehsan, Andrew Ip, Ivan De Dios, Wanlong Ma, Ipsa Sharma, James McCloskey, Michele Donato, David Sieg...> ;The American Journal of Pathology. 2023 Jan 1
23 citations
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study.
Paolo Andrea Zucali, Chia-Chi Lin, Bradley C Carthon, Todd M Bauer, Marcello Tucci, Antoine Italiano, Roberto Iacovelli, Wu-Chou Su, Christophe Massard, Mansoor Saleh,...> ;Journal for Immunotherapy of Cancer. 2022 Jan 1
7 citations
Phase 1 multicenter study of the HSP90 inhibitor SNX-5422 plus carboplatin and paclitaxel in patients with lung cancers
Martin Gutierrez, Robin Guo, Giuseppe Giaccone, Stephen V. Liu, Zhonglin Hao, Christie Hilton, James M Hinson, Mark G. Kris, Everardus Otto Orlemans, Alexander Drilon> ;Lung Cancer. 2021 Oct 8
17 citations
An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer.
Joyce F. Liu, Howard A. Burris, Judy S. Wang, Lisa Barroilhet, Martin Gutierrez, Yulei Wang, Anjali Vaze, Renee Commerford, Stephanie Royer-Joo, Voleak Choeurng, Eric ...> ;Gynecologic Oncology. 2021 Oct 6
14 citations
Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial.
Joël Guigay, Keun Wook Lee, Manish R. Patel, Amaury Daste, Deborah J. Wong, Sanjay Goel, Michael S. Gordon, Martin Gutierrez, Ani Sarkis Balmanoukian, Christophe Le To...> ;Journal for Immunotherapy of Cancer. 2021 Oct 1
11 citations
A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.
Florence Atrafi, Oliver Boix, Vivek Subbiah, Jennifer R. Diamond, Sant P. Chawla, Anthony W. Tolcher, Patricia LoRusso, Joseph Paul Eder, Martin Gutierrez, Kumar Sankh...> ;Clinical Cancer Research. 2021 Sep 13
9 citations
First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors.
Khanh T. Do, Laura Q.M. Chow, Karen L. Reckamp, Rachel E. Sanborn, Howard A. Burris, Francisco Robert, D. Ross Camidge, Conor E. Steuer, John H. Strickler, Amy Weise, ...> ;The Oncologist. 2021 Nov 1
6 citations
Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previou...
Byoung Chul Cho, Kiyotaka Yoh, Ruth Perets, Adnan Nagrial, David R. Spigel, Martin Gutierrez, Dong Wan Kim, Dusan Kotasek, Drew W. Rasco, Jiaxin Niu, Miyako Satouchi, ...> ;Lung Cancer. 2021 Jul 18
13 citations
A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors.
M. Puglisi, L Rhoda Molife, Maja J.A. de Jonge, Khurum Khan, Leni van Doorn, Martin Forster, Montserrat Blanco, Martin Gutierrez, Catherine Franklin, Todd Busman, Jian...> ;Future Oncology. 2021 Apr 14
20 citations
Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma.
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;JCI Insight. 2021 Mar 22
37 citations
OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors.
Martin Gutierrez, Victor Moreno, Kimberley M. Heinhuis, Anthony J. Olszanski, Anna Spreafico, Michael Ong, Quincy Chu, Richard D. Carvajal, Jose Manuel Trigo, Maria Oc...> ;Clinical Cancer Research. 2021 Jan 15
47 citations
Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer.
Ruth Perets, Jair Bar, Drew W. Rasco, Myung-Ju Ahn, Kiyotaka Yoh, Dong Wook Kim, Adnan Nagrial, Miyako Satouchi, D.H. Lee, David R. Spigel, Dusan Kotasek, Martin Gutie...> ;Annals of Oncology. 2021 Mar 1
2 citations
The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours.
Darcy B. Pooler, Dylan B. Ness, John Sarantopoulos, Nicholas Squittieri, Shoba Ravichandran, Carolyn D. Britten, Ravi K. Amaravadi, Ulka N. Vaishampayan, Patricia LoRu...> ;British Journal of Clinical Pharmacology. 2021 Mar 1
70 citations
A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies.
Philippe Armand, Alexander M. Lesokhin, Ivan Borrello, John M. Timmerman, Martin Gutierrez, Lili Zhu, Mihaela Popa McKiver, Stephen M. Ansell> ;Leukemia. 2021 Mar 1
15 citations
Genomic Profiling for KRAS, NRAS, BRAF, Microsatellite Instability, and Mismatch Repair Deficiency Among Patients With Metastatic Colon Cancer
Martin Gutierrez, Kristin Price, R.B. Lanman, Rebecca J. Nagy, Irfan Shah, Shivam Mathura, Michael Mulcahy, Andrew D. Norden, Stuart L. Goldberg> ;JCO Precision Oncology. 2019 Dec 6
27 citations
An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors.
Rui Wang, Chan Gao, Megan Raymond, Gennaro Dito, Dominic Kabbabe, Xiao Shao, Ed Hilt, Yongliang Sun, Irene Pak, Martin Gutierrez, Ignacio Melero, Anna Spreafico, Richa...> ;Clinical Cancer Research. 2019 Nov 15
65 citations
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC.
Scott J. Antonia, Ani Sarkis Balmanoukian, Julie R. Brahmer, Sai-Hong Ignatius Ou, Matthew D. Hellmann, Sang We Kim, Myung-Ju Ahn, Dong Wan Kim, Martin Gutierrez, Step...> ;Journal of Thoracic Oncology. 2019 Oct 1
68 citations
Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.
Andres Forero-Torres, Radhakrishnan Ramchandren, Abdulraheem Yacoub, Michael S. Wertheim, William Jeffery Edenfield, Paolo Caimi, Martin Gutierrez, Luke P. Akard, Caro...> ;Blood. 2019 Apr 18
381 citations
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Bioma...
Neal Ready, Matthew D. Hellmann, Mark M. Awad, Gregory A. Otterson, Martin Gutierrez, Justin F. Gainor, Hossein Borghaei, Jacques Jolivet, Leora Horn, Mihaela Mates, J...> ;Journal of Clinical Oncology. 2019 Feb 20
Join now to see all

Lectures

Utilization of next generation sequencing (NGS) and rates of undergenotyping in patients with metastatic colon cancer (mCC) treated at academic and community centers i...
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
Rates of genotyping for , , , microsatellite instability (MSI), and mismatch repair (MMR) in metastatic colon cancer patients: Gaps and implications.
ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
Biomarker-directed precision oncology of pembrolizumab-based combination therapy for non-small cell lung cancer: Phase II KEYNOTE-495/KeyImPaCT study.
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
Real-world characterization of advanced/metastatic non-small cell lung cancer (aNSCLC) patients (pts) with rapid disease progression (RDP).
ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
Join now to see all

Press Mentions

Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of CancerSeptember 5th, 2022
Molecular Tumor Testing Transformative, yet 'Under-Optimized'July 23rd, 2021
NextCure to Present Trials in Progress Poster for NC410 at the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingMay 19th, 2021
Join now to see all

Hospital Affiliations

Hackensack Meridian Health Hackensack University Medical CenterHackensack, New Jersey
Hackensack Meridian Health Jersey Shore University Medical CenterNeptune, New Jersey
Hackensack Meridian Health JFK University Medical CenterEdison, New Jersey
Hackensack Meridian Health Palisades Medical CenterNorth Bergen, New Jersey

Insurance Accepted

Aetna Choice POS II
Aetna HMO
AmeriHealth Direct POS
Amerihealth HMO
AmeriHealth PPO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
First Health PPO
GHI PPO
Great West PPO
Horizon BCBS Direct Access
Horizon BCBS HMO
Horizon BCBS POS
Horizon BCBS PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment